The effect of COVID-19 on hepatic enzymes AST/ALT: A review

Saba Ameli 1, Behnaz Mahmoodieh 1, Negin Dehghanipour 2, Ssara Babran 1 and Sanaz Saleh 1, *

1 Department of Medical Sciences, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
2 Department of pharmaceutical chemistry (pharmaceutical chemistry), Tehran Branch, Islamic Azad University, Tehran, Iran.
 
Review Article
Open Access Research Journal of Biology and Pharmacy, 2022, 05(02), 015–019.
Article DOI: 10.53022/oarjbp.2022.5.2.0053
Publication history: 
Received on 10 June 2022; revised on 16 July 2022; accepted on 18 July 2022
 
Abstract: 
The latest coronavirus pandemic, originated by the human coronavirus or SARS-CoV-2, has developed into a crucial global health affair over the past 2 years. These viruses are acclaimed to trigger a range of respiratory and enteric disorders in a diverse group of organisms and humans. Coronavirus have also been reported to cause respiratory failure, the complication of sepsis, and one or numerous organ failure. Several studies revealed that coronavirus-positive individuals had a liver injury. In those individuals, the increased levels of hepatic enzymes mainly AST and ALT and signs of inflammation were analyzed in complex clinical cases According to recent clinical data, abnormal levels of AST/ALT are more often noticed in coronavirus positive patients, but the fundamental pathogenesis is still not known entirely. We evaluated the current literature on COVID-19 and its effect on AST/ALT levels in coronavirus-positive patients.
 
Keywords: 
Covid-19; Hepatic enzymes; AST; ALT
 
Full text article in PDF: